Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
50,891 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07446322 | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer | recruiting | Phase 2 | 60 | Oncolytics BiotechINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07472322 | ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 | not yet recruiting | Phase 1 / Phase 2 | 31 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 |
| NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy | recruiting | Phase 3 | 670 | Boehringer IngelheimINDUSTRY | 42 | Sep 29, 2026 | clinicaltrials |
| NCT07488780 | Language Network Prehab Via fMRI Neurofeedback | recruiting | N/A | 4 | Yale UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07492316 | RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)(PNOC020 rMB) | active not recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07504588 | Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy | recruiting | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07529808 | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 164 | BigHat Biosciences, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07544654 | DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy | recruiting | Phase 3 | 390 | Boehringer IngelheimINDUSTRY | 29 | Sep 29, 2026 | clinicaltrials |
| NCT07551596 | Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial | recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07554339 | A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) | recruiting | Phase 3 | 310 | Merck Sharp & Dohme LLCINDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT07569926 | Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence | recruiting | Phase 4 | 142 | Blue Earth DiagnosticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07578571 | A Phase 1 Study of IM-1617 in Participants With Advanced Cancer | recruiting | Phase 1 | 175 | Immunome, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07603375 | Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma(TNT Esophagus) | recruiting | Phase 2 | 60 | Duke UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07605416 | Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial | recruiting | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07607678 | A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab | recruiting | Phase 1 | 60 | Boehringer IngelheimINDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT07659795 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer(TARGET-D 203) | recruiting | Phase 2 | 150 | Verastem, Inc.INDUSTRY | 2 | Sep 29, 2026 | clinicaltrials |
| NCT07705035 | DBC-664 in Adult Patients With Solid Tumors | recruiting | Phase 1 | 210 | Duboce Biopharmaceuticals, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07706179 | Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer | not yet recruiting | Phase 2 | 10 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07707895 | DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers | not yet recruiting | Phase 1 / Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT07725172 | Radiation Therapy and Thymus Function in Young Women With Breast Cancer | recruiting | — | 125 | Duke UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07755176 | Patient-reported Outcomes Following Percutaneous Ablation of Desmoid Tumors | enrolling by invitation | — | 30 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07766187 | Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma(CODAH) | not yet recruiting | Phase 2 | 12 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07787247 | Feasibility of Remote Monitoring of Patients With Myasthenia Gravis(ROME-MG) | recruiting | — | 18 | George Washington UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07819136 | REC-7735 in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 90 | Recursion Pharmaceuticals Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845617 | Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma | recruiting | — | 10 | AdventHealthOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847957 | Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL | not yet recruiting | Phase 1 / Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00001254 | Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome | completed | — | 273 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00001276 | Diagnosing and Treating Low Blood Sugar Levels | recruiting | — | 1,500 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00001465 | Study of the Disease Process of Lymphangioleiomyomatosis | recruiting | — | 2,000 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00001620 | Screening for Hematology Branch Protocols | enrolling by invitation | — | 10,000 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00001813 | Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy | completed | — | 709 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00001975 | Study of Skin Tumors in Tuberous Sclerosis | recruiting | — | 400 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00005927 | Study of Adrenal Gland Tumors | completed | — | 690 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00006421 | Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study | completed | — | 200 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00006518 | Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer | recruiting | — | 1,029 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00024804 | A Natural History Study of Bone and Mineral Disorders | recruiting | — | 1,000 | National Institute of Dental and Craniofacial Research (NIDCR)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00033137 | Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer | recruiting | — | 950 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00034216 | Collection of Blood From Patients With Cancer | recruiting | — | 1,750 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00040222 | Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer | completed | — | 377 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00040352 | Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma | recruiting | — | 3,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00043472 | Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk | completed | — | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00068003 | Harvesting Cells for Experimental Cancer Treatments | enrolling by invitation | — | 7,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00071045 | Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members | enrolling by invitation | — | 6,000 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00092222 | Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | active not recruiting | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00314119 | Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 | completed | — | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00475761 | Breast Mammogram and Tissue Study | completed | — | 466 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00646022 | Natural History of Familial Carcinoid Tumor | recruiting | — | 1,600 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 28, 2026 | clinicaltrials |
Data updated yesterdaySource updated unknownsource: clinicaltrials